Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

Recruiting now

Conditions studied: Acute Myeloid Leukemia

In brief

The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.

Key facts

Study ID

NCT06535113

Run by

Ciceri Fabio

People needed

80

Starts

2025-02-22

Expected to finish

2026-08-31

Last updated by the study team

2026-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any gender,
• Adults (>18 years old),
• New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)
• Capable of comprehend the study and the consent form,
• Willing to sign the informed consent for the study.
• For the retrospective population we will select:
• biological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.

You may not qualify if…

• Pediatric patients (<18 years old),
• Patients unable or unwilling to sign the informed consent.

Where it is running

• GOM Bianchi Melacrino Morelli — Reggio Calabria, Calabria, Italy (enrolling)
• IRCCS Ospedale San Raffaele — Milan, Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.